Nitrosamine Impurities
Nitrosamines are a class of potent, probably-carcinogenic impurities that, since 2018, have driven one of the largest and longest-running quality events in the history of the pharmaceutical industry — mass recalls, a mandated risk assessment of essentially every marketed medicine, and an evolving regulatory framework that is still moving. They matter to every GxP practitioner because the response defined a template for how the industry handles a newly-recognised, cross-cutting impurity risk. Because the specific limits and the list of affected products change continually, this page explains the durable concepts and treats the moving detail as something to track through live regulatory intelligence rather than memorise. The risk method underneath it all is the [quality risk management](/topics/quality-risk-management) explainer.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 23 LINKSSince valsartan in 2018, nitrosamines forced a whole-portfolio, risk-based impurity assessment across the industry — a living GMP obligation whose acceptable-intake limits keep moving, so track the numbers, hold the framework.
06 · QUALITY MATURITY — NITROSAMINE IMPURITIES, REACTIVE TO ADAPTIVE
Nitrosamine risk is addressed only when a regulator or a recall forces it, product by product.
A risk-assessment procedure exists, but it is a one-time exercise not revisited as new NDSRIs and limits emerge.
Every product is assessed against known formation routes; ICH M7 acceptable intakes drive confirm-and-control where risk is found.
Supply-chain and process-change signals are screened for nitrosamine potential before an impurity forms in the product.
Nitrosamine risk is designed out at route and formulation, and the assessment stays live as toxicology and regulatory limits move.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 3
Derived from the 3 standards SPEQ maps to this subject, across 2 regulatory bodies: FDA, ICH.
RECORDS & OBJECTIVE EVIDENCE
- Portfolio-wide nitrosamine risk assessments covering API, excipient, and NDSRI formation routes
- Confirmatory testing (e.g. LC-MS/GC-MS) where risk was identified
- Acceptable-intake justifications per ICH M7(R1) and current nitrosamine guidance
- Change-control records assessing process changes for nitrosamine impact
- Supplier and raw-material controls for reagents, recovered solvents, and vendor sources
COMMON INSPECTION FINDINGS
- No portfolio risk assessment for nitrosamine presence
- A process change assessed without evaluating impurity formation
- NDSRI formation in the drug product never considered
- Control levels not justified against a compound-specific acceptable intake
- Risk assessment treated as closed rather than kept current as limits change
How a class of impurities became an industry-wide event
In July 2018, regulators were informed that a nitrosamine impurity — N-nitrosodimethylamine (NDMA), a probable human carcinogen — was present in valsartan, a widely used blood-pressure medicine, and had been for years following a manufacturing-process change. What began as a single-product problem rapidly widened: NDMA and related nitrosamines (NDEA and others) were found across the sartan class, then in ranitidine, metformin, and further products, triggering waves of recalls and a fundamental question — how many marketed medicines might carry nitrosamines that no one had looked for?
The regulatory response was unprecedented in scope: authorities required marketing-authorisation holders to conduct a **risk assessment of essentially their entire portfolio** for the potential presence of nitrosamines, in defined phases — first assess the risk, then confirm by testing where risk was identified, then implement changes to control or eliminate them. This turned a specific contamination finding into a standing, whole-industry control obligation, and it is why nitrosamines is not a niche impurity topic but a defining GMP event of the past several years.
Where nitrosamines come from
Understanding the risk means understanding the many routes by which nitrosamines form or enter a product, because the sources turned out to be more numerous than first assumed. They can arise in the **API manufacturing process** (the original valsartan route, where specific reagents and solvents under certain conditions generated NDMA); from **contaminated raw materials, reagents, or recovered solvents**; from **vendor-related sources** in the supply chain; and — the source that expanded the problem dramatically — from the **drug product itself**, where a nitrosating agent can react with an amine in the API or an excipient to form a nitrosamine specific to that drug. This last category, the **nitrosamine drug-substance-related impurities (NDSRIs)**, meant that even products with clean APIs could form nitrosamines in the finished formulation.
The breadth of these root causes is the reason the risk assessment had to span the whole portfolio rather than target a few suspect molecules: almost any product combining an amine and a possible nitrosating source under the right conditions could, in principle, be at risk. It also made this a genuine quality-risk-management exercise — evaluating each product against the known formation routes, prioritising by likelihood and by the potency of any nitrosamine that could form, and controlling proportionately, rather than blanket-testing everything to the same depth.
The control framework — and why it keeps moving
Nitrosamines are mutagenic impurities, so they are governed by the framework for **DNA-reactive (mutagenic) impurities, ICH M7(R1)**, which sets out how such impurities are assessed and controlled to limit carcinogenic risk, together with dedicated FDA and EMA nitrosamine guidances. Control works through an **acceptable intake (AI)** concept: a compound-specific daily-exposure limit derived from its carcinogenic potency and corresponding to a defined, very low lifetime cancer risk, against which the actual level in the product is controlled. Where a nitrosamine cannot be avoided entirely, it must be held below its AI through process and formulation controls.
The reason this page deliberately does **not** print specific AI values or lists of affected products is that they change continually: acceptable-intake limits for individual nitrosamines have been set, revised, and added to as toxicological data and new NDSRIs emerge; the methods for setting limits for novel NDSRIs (such as read-across and enhanced Ames testing) are themselves evolving; and deadlines and product lists shift. A number transcribed today can be wrong within months. The durable knowledge is the framework — risk assessment, formation routes, ICH M7 and the AI concept, phased confirm-and-control; the current numbers belong in live regulatory intelligence, which is exactly the kind of moving limit SPEQ tracks through its feeds rather than freezing into a reference page.
The lasting lessons for the quality system
Beyond the specific chemistry, nitrosamines left the industry with transferable lessons. It proved that a **manufacturing-process change** — the seemingly routine kind managed through change control — can introduce a serious, undetected impurity if its impact on impurity formation is not fully assessed, sharpening the expectation that change control and impurity risk assessment must reach for the unexpected. It showed that **supply-chain visibility** matters: nitrosamines entered through reagents, recovered solvents, and vendor materials, so a control strategy is only as good as the knowledge of what is actually in the inputs. And it demonstrated the value of a **portfolio-level, risk-based** response over product-by-product firefighting.
For the quality system, nitrosamines is the case study in handling a newly-recognised cross-cutting risk: assess broadly and by risk, confirm by testing where warranted, control proportionately to potency and exposure, and keep the assessment live as the science and the regulatory limits move. Treating it as "solved" would be the error — it remains an active, evolving area, which is precisely why the practitioner’s job is to hold the durable framework in mind and watch the current detail through live intelligence rather than a static number.
FREQUENTLY ASKED
What are nitrosamine impurities and why do they matter?
Nitrosamines are a class of potent, probably-carcinogenic impurities. Since a nitrosamine (NDMA) was found in valsartan in July 2018, they have driven mass recalls and a regulator-mandated risk assessment of essentially every marketed medicine for their potential presence. They matter to every GxP practitioner because the response defined how the industry handles a newly-recognised, cross-cutting impurity risk.
Where do nitrosamines in drugs come from?
From several routes: the API manufacturing process (specific reagents/solvents under certain conditions); contaminated raw materials, reagents, or recovered solvents; vendor and supply-chain sources; and the drug product itself, where a nitrosating agent reacts with an amine in the API or an excipient to form a nitrosamine drug-substance-related impurity (NDSRI). The breadth of these routes is why the risk assessment had to span whole portfolios rather than a few molecules.
How are nitrosamines controlled?
As mutagenic impurities they fall under the ICH M7(R1) framework for DNA-reactive impurities, plus dedicated FDA and EMA nitrosamine guidances. Control uses an acceptable intake (AI) concept — a compound-specific daily-exposure limit derived from carcinogenic potency and a defined very low lifetime cancer risk — against which the actual level is held. Where a nitrosamine cannot be avoided, process and formulation controls keep it below its AI.
Why doesn’t this page list the specific nitrosamine limits?
Because they change continually — acceptable-intake limits are revised and added as toxicological data and new NDSRIs emerge, the methods for setting limits for novel NDSRIs are evolving, and deadlines and product lists shift, so a number transcribed today can be wrong within months. The durable knowledge is the framework (risk assessment, formation routes, ICH M7, the AI concept); the current numbers belong in live regulatory intelligence, which SPEQ tracks through its feeds.